title: Behavioral architecture of opioid reward and aversion in C57BL/6 substrains.
abstract: Drug liking vs. drug disliking is a subjective motivational measure in humans that assesses the addiction liability of drugs. Variation in this trait is hypothesized to influence vulnerability vs. resilience toward substance abuse disorders and likely contains a genetic component. In rodents and humans, conditioned place preference (CPP)/aversion (CPA) is a Pavlovian conditioning paradigm whereby a learned preference for the drug-paired environment is used to infer drug liking whereas a learned avoidance or aversion is used to infer drug disliking. C57BL/6 inbred mouse substrains are nearly genetically identical, yet demonstrate robust differences in addiction-relevant behaviors, including locomotor sensitization to cocaine and consumption of ethanol. Here, we tested the hypothesis that B6 substrains would demonstrate differences in the rewarding properties of the mu opioid receptor agonist oxycodone (5 mg/kg, i.p.) and the aversive properties of the opioid receptor antagonist naloxone (4 mg/kg, i.p.). Both substrains showed similar degrees of oxycodone-induced CPP; however, there was a three-fold enhancement of naloxone-induced CPA in agonist-naïve C57BL/6J relative to C57Bl/6NJ mice. Exploratory factor analysis of CPP and CPA identified unique factors that explain variance in behavioral expression of reward vs. aversion. "Conditioned Opioid-Like Behavior" was a reward-based factor whereby drug-free locomotor variables resembling opioid treatment co-varied with the degree of CPP. "Avoidance and Freezing" was an aversion-based factor, whereby the increase in the number of freezing bouts co-varied with the degree of aversion. These results provide new insight into the behavioral architecture of the motivational properties of opioids. Future studies will use quantitative trait locus mapping in B6 substrains to identify novel genetic factors that contribute to the marked strain difference in NAL-CPA.
authors: Laboratory of Addiction Genetics, Pharmacology and Experimental Therapeutics, Boston University School of Medicine Boston, MA, USA.
authors: Stacey L
authors: SL
authors: Kirkpatrick
authors: Laboratory of Addiction Genetics, Pharmacology and Experimental Therapeutics, Boston University School of Medicine Boston, MA, USA.
authors: Camron D
authors: CD
authors: Bryant
keywords: dysphoria; euphoria; factor analysis; motivated behavior; naltrexone; opioid; quantitative trait locus; substrain
references: Ann N Y Acad Sci. 2011 Dec;1245:31-3
references: 22211972
references: Addict Biol. 2014 Jul;19(4):552-61
references: 23231598
references: J Pharmacol Exp Ther. 1994 Dec;271(3):1391-8
references: 7996451
references: Psychopharmacology (Berl). 1985;86(3):281-5
references: 2863837
references: Behav Neurosci. 2006 Feb;120(1):10-5
references: 16492112
references: Drug Alcohol Depend. 1983 Apr;11(2):147-65
references: 6134605
references: Behav Brain Res. 2005 May 7;160(1):34-43
references: 15836898
references: Am J Drug Alcohol Abuse. 1992;18(3):275-87
references: 1329491
references: Neuropsychopharmacology. 2006 Jan;31(1):171-7
references: 15956992
references: Neurosci Lett. 2008 Oct 3;443(2):108-12
references: 18662746
references: Eur J Neurosci. 2005 Mar;21(5):1379-84
references: 15813947
references: Psychopharmacology (Berl). 2004 Mar;172(2):129-36
references: 14624329
references: Biol Psychiatry. 2008 Dec 1;64(11):989-97
references: 18589403
references: Nature. 2011 Sep 14;477(7364):289-94
references: 21921910
references: J Pharmacol Exp Ther. 1992 Jan;260(1):355-63
references: 1731046
references: Pain Physician. 2014 Mar-Apr;17(2):E119-28
references: 24658483
references: Neuroscience. 2004;124(1):241-6
references: 14960355
references: Addict Biol. 2006 Sep;11(3-4):397-403
references: 16961767
references: Anesthesiology. 2012 Jul;117(1):22-37
references: 22713632
references: Clin Pharmacol Ther. 2010 Dec;88(6):779-91
references: 20981002
references: Eur J Pain. 2011 Mar;15(3):299-305
references: 20801699
references: Nat Rev Genet. 2005 Jul;6(7):521-32
references: 15995696
references: Eur J Pharmacol. 2009 Jan 14;602(2-3):321-7
references: 19071107
references: Am J Psychiatry. 1985 Sep;142(9):1081-4
references: 2992300
references: Psychopharmacology (Berl). 2009 Dec;207(2):245-55
references: 19787337
references: Eur J Pharmacol. 2010 Oct 25;645(1-3):119-26
references: 20674566
references: Pain Med. 2011 Apr;12(4):618-31
references: 21463474
references: Drug Alcohol Depend. 2009 Jul 1;103(1-2):74-83
references: 19419821
references: Psychopharmacology (Berl). 2012 Feb;219(4):999-1009
references: 21833503
references: Psychopharmacology (Berl). 2001 Apr;155(1):35-42
references: 11374334
references: Brain Res. 1977 Mar 4;123(1):180-7
references: 843917
references: Pharmacology. 2011;87(5-6):286-96
references: 21577043
references: Neuroscience. 2001;106(4):757-63
references: 11682161
references: Psychopharmacology (Berl). 1984;82(3):241-7
references: 6425908
references: Biol Psychiatry. 1987 Jun;22(6):710-6
references: 3593812
references: Psychopharmacology (Berl). 1990;101(3):332-7
references: 2163538
references: J Psychopharmacol. 2010 Jun;24(6):875-80
references: 19164501
references: Psychiatr Clin North Am. 2012 Jun;35(2):495-519
references: 22640768
references: Biol Psychiatry. 2009 May 15;65(10):900-4
references: 19111278
references: Addict Biol. 2013 Nov;18(6):985-92
references: 22129527
references: Int J Drug Policy. 2014 Mar;25(2):257-66
references: 24238956
references: Pain Med. 2012 Jun;13(6):790-801
references: 22568663
references: J Neurogenet. 2008;22(4):315-31
references: 19085272
references: Front Genet. 2012 Jul 11;3:126
references: 22798962
references: Life Sci. 1983;33 Suppl 1:393-6
references: 6686635
references: CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22
references: 20201811
references: Addict Biol. 2007 Sep;12(3-4):227-462
references: 17678505
references: J Pharmacol Exp Ther. 1977 Nov;203(2):347-59
references: 561844
references: Biol Psychiatry. 1992 Aug 15;32(4):344-53
references: 1420648
references: Genes Brain Behav. 2012 Jul;11(5):623-32
references: 22487465
references: Nature. 1996 Oct 31;383(6603):819-23
references: 8893006
references: Eur J Pharmacol. 1979 Jun;56(1-2):75-80
references: 572778
references: Pharmacol Biochem Behav. 2013 Sep;110:112-6
references: 23827650
references: Science. 2013 Dec 20;342(6165):1508-12
references: 24357318